Centrally administered MTII affects feeding, drinking, temperature, and activity in the Sprague-Dawley rat.

Murphy B, Nunes CN, Ronan JJ, Hanaway M, Fairhurst AM, Mellin TN

Journal of applied physiology (Bethesda, Md. : 1985)1 Jul 2000Cited by 57 (Europe PMC)

PMID10904062DOI10.1152/jappl.2000.89.1.273PepBankPUB-10904062

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In Sprague-Dawley rats, a low intracerebroventricular dose of MTII (0.05 ng) reduced feeding.
In plain wordsIn rats, a very low dose of MTII given into the brain reduced feeding.
Peptide
Melanotan II
Outcome
DecreaseNocturnal feeding at low dose
Study
ratn: not reported in source
Sprague-Dawley rat
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
0.05 ng · intracerebroventricular (third ventricle)As given in this study (rat).
Measurements
dose
0.05 ng
low dose
Source sentences
Summary
Low doses of MTII (0.05 ng) caused reductions in feeding without alterations in body temperature, drinking, or activity.
1 context sentence(design, population, supporting numbers)
Summary · context
Accordingly, we performed studies to simultaneously measure nocturnal feeding, drinking, activity, and temperature of rats after intracerebroventricular (third ventricle) administration of a wide dose range of MTII (0.05-500 ng).
Report a problemFND-1090406201
02AnimalAnimal study (in vivo)Efficacy outcome
In Sprague-Dawley rats, a low intracerebroventricular dose of MTII (0.05 ng) did not alter body temperature.
In plain wordsIn rats, a very low dose of MTII given into the brain did not change body temperature.
Peptide
Melanotan II
Outcome
No significant changeBody temperature at low dose
Study
ratn: not reported in source
Sprague-Dawley rat
Outcome group
Body temperature · Whole body
Studied dose
0.05 ng · intracerebroventricular (third ventricle)As given in this study (rat).
Source sentences
Summary
Low doses of MTII (0.05 ng) caused reductions in feeding without alterations in body temperature, drinking, or activity.
1 context sentence(design, population, supporting numbers)
Summary · context
Accordingly, we performed studies to simultaneously measure nocturnal feeding, drinking, activity, and temperature of rats after intracerebroventricular (third ventricle) administration of a wide dose range of MTII (0.05-500 ng).
Report a problemFND-1090406202
03AnimalAnimal study (in vivo)Efficacy outcome
In Sprague-Dawley rats, a low intracerebroventricular dose of MTII (0.05 ng) did not alter drinking.
In plain wordsIn rats, a very low dose of MTII given into the brain did not change drinking.
Peptide
Melanotan II
Outcome
No significant changeDrinking at low dose
Study
ratn: not reported in source
Sprague-Dawley rat
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
0.05 ng · intracerebroventricular (third ventricle)As given in this study (rat).
Source sentences
Summary
Low doses of MTII (0.05 ng) caused reductions in feeding without alterations in body temperature, drinking, or activity.
1 context sentence(design, population, supporting numbers)
Summary · context
Accordingly, we performed studies to simultaneously measure nocturnal feeding, drinking, activity, and temperature of rats after intracerebroventricular (third ventricle) administration of a wide dose range of MTII (0.05-500 ng).
Report a problemFND-1090406203
04AnimalAnimal study (in vivo)Efficacy outcome
In Sprague-Dawley rats, a low intracerebroventricular dose of MTII (0.05 ng) did not alter activity.
In plain wordsIn rats, a very low dose of MTII given into the brain did not change activity.
Peptide
Melanotan II
Outcome
No significant changeActivity at low dose
Study
ratn: not reported in source
Sprague-Dawley rat
Outcome group
Exercise and physical function · Whole body
Studied dose
0.05 ng · intracerebroventricular (third ventricle)As given in this study (rat).
Source sentences
Summary
Low doses of MTII (0.05 ng) caused reductions in feeding without alterations in body temperature, drinking, or activity.
1 context sentence(design, population, supporting numbers)
Summary · context
Accordingly, we performed studies to simultaneously measure nocturnal feeding, drinking, activity, and temperature of rats after intracerebroventricular (third ventricle) administration of a wide dose range of MTII (0.05-500 ng).
Report a problemFND-1090406204
05AnimalAnimal study (in vivo)Efficacy outcome
In Sprague-Dawley rats, intracerebroventricular MTII at doses above 50 ng reduced food intake.
In plain wordsIn rats, MTII given into the brain at higher doses reduced food intake.
Peptide
Melanotan II
Outcome
DecreaseFood intake at high dose
Study
ratn: not reported in source
Sprague-Dawley rat
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
>50 ng · intracerebroventricular (third ventricle)As given in this study (rat).
Source sentences
Summary
In contrast, hyperthermia and disrupted drinking patterns, along with food intake reductions, were evident at doses exceeding 50 ng.
1 context sentence(design, population, supporting numbers)
Summary · context
Accordingly, we performed studies to simultaneously measure nocturnal feeding, drinking, activity, and temperature of rats after intracerebroventricular (third ventricle) administration of a wide dose range of MTII (0.05-500 ng).
Report a problemFND-1090406205
06AnimalAnimal study (in vivo)Safety outcome
In Sprague-Dawley rats, intracerebroventricular MTII at doses above 50 ng caused hyperthermia.
In plain wordsIn rats, MTII given into the brain at higher doses raised body temperature.
Peptide
Melanotan II
Outcome
IncreaseBody temperature at high dose
Study
ratn: not reported in source
Sprague-Dawley rat
Outcome group
Adverse events · Whole body
Studied dose
>50 ng · intracerebroventricular (third ventricle)As given in this study (rat).
Source sentences
Summary
In contrast, hyperthermia and disrupted drinking patterns, along with food intake reductions, were evident at doses exceeding 50 ng.
1 context sentence(design, population, supporting numbers)
Summary · context
Accordingly, we performed studies to simultaneously measure nocturnal feeding, drinking, activity, and temperature of rats after intracerebroventricular (third ventricle) administration of a wide dose range of MTII (0.05-500 ng).
Report a problemFND-1090406206
07AnimalAnimal study (in vivo)Safety outcome
In Sprague-Dawley rats, intracerebroventricular MTII at doses above 50 ng disrupted drinking patterns.
In plain wordsIn rats, MTII given into the brain at higher doses disrupted normal drinking patterns.
Peptide
Melanotan II
Outcome
Direction not reportedDrinking patterns at high dose
Study
ratn: not reported in source
Sprague-Dawley rat
Outcome group
Adverse events · Whole body
Studied dose
>50 ng · intracerebroventricular (third ventricle)As given in this study (rat).
Source sentences
Summary
In contrast, hyperthermia and disrupted drinking patterns, along with food intake reductions, were evident at doses exceeding 50 ng.
1 context sentence(design, population, supporting numbers)
Summary · context
Accordingly, we performed studies to simultaneously measure nocturnal feeding, drinking, activity, and temperature of rats after intracerebroventricular (third ventricle) administration of a wide dose range of MTII (0.05-500 ng).
Report a problemFND-1090406207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.